Previous close | 3.8900 |
Open | 3.9000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.8500 - 3.9900 |
52-week range | 2.8240 - 18.5000 |
Volume | |
Avg. volume | 57,648 |
Market cap | 21.374M |
Beta (5Y monthly) | -0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript April 2, 2024 Evaxion Biotech A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the […]
With the business potentially at an important milestone, we thought we'd take a closer look at Evaxion Biotech A/S...